Opinion on Pharmaceuticals in Middle East and Africa

Published within

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Boehringer Ingelheim: Mirapex once-daily development on-track but commercial potential unclear

Recently released data show that the Mirapex once-daily formulation was superior to placebo in early Parkinson's disease patients, and comparable with the thrice-daily version of the drug. With generic versions of Mirapex expected in early 2010, the development of this reformulation may be too late to prevent significant revenue loss for Boehringer Ingelheim.

Published By Datamonitor
01 May 2009
CommentWire
CommentWire

Bristol-Myers Squibb: arthritis antibody bolsters pipeline but competition will limit impact

Bristol-Myers Squibb has signed a licensing agreement with Alder Pharmaceuticals for its anti-IL-6 rheumatoid arthritis candidate, ALD518. Prior to the deal, Bristol-Myers Squibb's pipeline was thin, with only two late-stage agents in this indication. However, if approved, ALD518 will face significant competition from Actemra as well as more promising pipeline agents that may limit its impact.

Published By Datamonitor
11 Nov 2009
Expert View
Expert View

Can biologic drugs tackle antibiotic resistance?

Antibody-based products present a novel approach to the treatment and prevention of infections, as an alternative to conventional antibiotics. Several companies are developing such agents for a range of indications, but their cost, complex manufacturing methods and mode of administration are restrictive. A high unmet need and well defined target groups are key to commercial success in this market.

Published By Datamonitor
30 Apr 2008
CommentWire
CommentWire

Can-Fite: therapeutic approach bolstered by positive results in psoriasis trial

CF101, an orally-available TNF-alpha antagonist, has shown promising results in a Phase IIa study for the treatment of moderate to severe psoriasis. With current therapies focused on topical agents and biologics, this interesting oral compound has potential benefits for an unmet need in the treatment of psoriasis.

Published By Datamonitor
09 Sep 2009
CommentWire
CommentWire

Celiac disease: improved diagnosis potential highlights untapped market

A new study has highlighted the benefit of routine antibody testing in suspected cases of celiac disease. While these data prove the merit of serological testing, awareness of the disease remains a significant issue. Indeed, with almost no treatment options available, the development of an effective pharmacological therapy offers the potential to reap significant returns from this untapped market.

Published By Datamonitor
21 Dec 2009
CommentWire
CommentWire

Cell Therapeutics: pixantrone close to extending lymphoma treatment options

Having reported positive follow-up results for pixantrone from the pivotal Phase III EXTEND trial, Cell Therapeutics has now submitted a marketing application with the FDA for the drug in relapsed/refractory, aggressive non-Hodgkin's lymphoma. Pixantrone's chance of approval looks promising as it addresses an important unmet need for more effective third-line therapies in this population.

Published By Datamonitor
24 Jun 2009
CommentWire
CommentWire

Cipla: lobbying for more generics in South Africa

Generics maker Cipla is trying to cut a deal to supply South African mining firm Anglo American with HIV drugs. Employer provision of HIV medicine is gaining popularity in South Africa, and last year's court case created the opportunity for the government to license generic versions of patented drugs. However, it has so far been reluctant to use this power.

Published By Datamonitor
20 Aug 2002
CommentWire
CommentWire

Concert: protease inhibitor holds potential to be prescribed un-boosted

US healthcare firm Concert Pharmaceuticals has initiated a Phase Ib study for its protease inhibitor CTP-518. Early data on the candidate suggest that, unlike many marketed protease inhibitors, it does not require ritonavir boosting. Datamonitor believes that if these results are confirmed in larger studies, the compound has a strong chance of gaining commercial success.

Published By Datamonitor
10 Nov 2009
CommentWire
CommentWire

Cubist Pharmaceuticals/Teva: US generics deal agreed for Cubicin

Cubist Pharmaceuticals has granted Teva a non-exclusive license to launch a generic version of its antibiotic Cubicin in the US. The move brings the dispute - which had been running since 2009 - to a close, and eliminates the risk of Cubist losing Cubicin sales in the event of Teva winning the patent litigation.

Published By Datamonitor
08 Apr 2011
ResearchWire
ResearchWire

Cystic fibrosis: enzymes and antibiotics dominate the pipeline

Published By Datamonitor
30 Mar 2006

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

No help is available.